To address this, CAR T cells were engineered with a PD-1-CD28 switch receptor (αM.CAR/SR T cells), which enhanced cytotoxicity against CCA cells expressing both MUC1 and PD-L1. The gene discussed is PDCD1; the disease is cholangiocarcinoma.